Evolving to an Ideal Synthesis of Molnupiravir, an Investigational Treatment for COVID-19

Tamas Benkovics(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patrick S. Fier(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hsing‐I Ho(Merck & Co., Inc., Rahway, NJ, USA (United States)), Neil A. Strotman(Merck & Co., Inc., Rahway, NJ, USA (United States)), William Morris(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jongrock Kong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark D. Huffman(Northwestern University), Grant S. Murphy(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. McIntosh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jessica Hurtak(Codexis (United States)), Deeptak Verma(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin M. Maloney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anders M. Knight(California Institute of Technology), Tetsuji Itoh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Weilan Pan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter E. Maligres(Merck & Co., Inc., Rahway, NJ, USA (United States)), Steven H. Silverman(RTX (United States)), Jonathan Vroom(Merck & Co., Inc., Rahway, NJ, USA (United States))
ChemRxiv
December 22, 2020
Cited by 36


Related Papers